FDA Approves Bayer HealthCare’s Betaconnect

The FDA has approved Bayer HealthCare’s Betaconnect, an electronic autoinjector for the treatment of relapsing-remitting multiple sclerosis.

Betaconnect will be available in early 2016 to patients taking Betaseron, a drug used to reduce the number of relapses in people with relapsing forms of MS.

The device offers customizable injection speed and depth settings at the push of a button. Patients can inject the drug quietly and with precision, the Leverkusen, Germany, drugmaker says.

The device is also equipped with automatic needle insertion and retraction and visual and audio end-of-dose indication, which lets patients know when the injection is complete. — Michael Cipriano